Breadcrumb navigation

Featured Press release

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

  • Session title: Phase I Clinical Trials 2
  • Poster and abstract number: CT182
  • Date, time, location: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT,
    Board 7, Section 33
  • Authors: M. Block, JP Delord, C. Ottensmeier, C. Le Tourneau, A. Lalanne, O. Lantz, K. Knutson, G. Lacoste, A. Tavernaro, M. Brandely, N. Silvestre, B. Grellier, Y. Yamashita, O. Kousuke, N. Yamagata, E. Quemeneur, K. Bendjama

Links: new windowPDF of actual poster


Press release

Read more

In the News